MYRIAD GENETICS INC (MYGN) Fundamental Analysis & Valuation

NASDAQ:MYGN • US62855J1043

Current stock price

4.35 USD
-0.09 (-2.03%)
At close:
4.35 USD
0 (0%)
After Hours:

This MYGN fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

2

1. MYGN Profitability Analysis

1.1 Basic Checks

  • In the past year MYGN was profitable.
  • In the past year MYGN had a positive cash flow from operations.
  • MYGN had negative earnings in each of the past 5 years.
  • The reported operating cash flow has been mixed in the past 5 years: MYGN reported negative operating cash flow in multiple years.
MYGN Yearly Net Income VS EBIT VS OCF VS FCFMYGN Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 100M -100M -200M -300M

1.2 Ratios

  • Looking at the Return On Assets, with a value of -51.78%, MYGN is in line with its industry, outperforming 46.03% of the companies in the same industry.
  • MYGN has a Return On Equity (-99.43%) which is in line with its industry peers.
Industry RankSector Rank
ROA -51.78%
ROE -99.43%
ROIC N/A
ROA(3y)-29.05%
ROA(5y)-19.71%
ROE(3y)-50.4%
ROE(5y)-33.33%
ROIC(3y)N/A
ROIC(5y)N/A
MYGN Yearly ROA, ROE, ROICMYGN Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 -20 -40 -60 -80

1.3 Margins

  • With an excellent Gross Margin value of 69.93%, MYGN belongs to the best of the industry, outperforming 80.08% of the companies in the same industry.
  • In the last couple of years the Gross Margin of MYGN has remained more or less at the same level.
  • MYGN does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 69.93%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.14%
GM growth 5Y-0.26%
MYGN Yearly Profit, Operating, Gross MarginsMYGN Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 -20 40 -40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

3

2. MYGN Health Analysis

2.1 Basic Checks

  • MYGN does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • MYGN has more shares outstanding than it did 1 year ago.
  • The number of shares outstanding for MYGN has been increased compared to 5 years ago.
  • Compared to 1 year ago, MYGN has a worse debt to assets ratio.
MYGN Yearly Shares OutstandingMYGN Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 20M 40M 60M 80M
MYGN Yearly Total Debt VS Total AssetsMYGN Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B 1.5B

2.2 Solvency

  • MYGN has an Altman-Z score of -0.30. This is a bad value and indicates that MYGN is not financially healthy and even has some risk of bankruptcy.
  • MYGN has a Altman-Z score (-0.30) which is in line with its industry peers.
  • A Debt/Equity ratio of 0.33 indicates that MYGN is not too dependend on debt financing.
  • With a Debt to Equity ratio value of 0.33, MYGN is not doing good in the industry: 68.47% of the companies in the same industry are doing better.
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Altman-Z -0.3
ROIC/WACCN/A
WACC9.68%
MYGN Yearly LT Debt VS Equity VS FCFMYGN Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 200M 400M 600M 800M 1B

2.3 Liquidity

  • MYGN has a Current Ratio of 2.49. This indicates that MYGN is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of MYGN (2.49) is worse than 70.21% of its industry peers.
  • MYGN has a Quick Ratio of 2.26. This indicates that MYGN is financially healthy and has no problem in meeting its short term obligations.
  • MYGN has a worse Quick ratio (2.26) than 72.34% of its industry peers.
Industry RankSector Rank
Current Ratio 2.49
Quick Ratio 2.26
MYGN Yearly Current Assets VS Current LiabilitesMYGN Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 100M 200M 300M 400M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. MYGN Growth Analysis

3.1 Past

  • The earnings per share for MYGN have decreased strongly by -53.85% in the last year.
  • MYGN shows a decrease in Revenue. In the last year, the revenue decreased by -1.56%.
  • MYGN shows a small growth in Revenue. Measured over the last years, the Revenue has been growing by 5.24% yearly.
EPS 1Y (TTM)-53.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
Revenue 1Y (TTM)-1.56%
Revenue growth 3Y6.72%
Revenue growth 5Y5.24%
Sales Q2Q%-0.38%

3.2 Future

  • The Earnings Per Share is expected to grow by 62.18% on average over the next years. This is a very strong growth
  • The Revenue is expected to grow by 4.76% on average over the next years.
EPS Next Y1.24%
EPS Next 2Y77.53%
EPS Next 3Y71.77%
EPS Next 5Y62.18%
Revenue Next Year5.08%
Revenue Next 2Y5.22%
Revenue Next 3Y5.18%
Revenue Next 5Y4.76%

3.3 Evolution

  • The Revenue growth rate is stable: in the next years the growth will be about the same than in the last years.
MYGN Yearly Revenue VS EstimatesMYGN Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 200M 400M 600M 800M 1B
MYGN Yearly EPS VS EstimatesMYGN Yearly EPS VS EstimatesYearly EPS VS Estimates 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 0 0.5 -0.5 1 1.5

More info and screens

Find the best growth stocksShow best growing peers

2

4. MYGN Valuation Analysis

4.1 Price/Earnings Ratio

  • A Price/Earnings ratio of 72.50 indicates a quite expensive valuation of MYGN.
  • Based on the Price/Earnings ratio, MYGN is valued cheaply inside the industry as 89.56% of the companies are valued more expensively.
  • When comparing the Price/Earnings ratio of MYGN to the average of the S&P500 Index (26.78), we can say MYGN is valued expensively.
  • A Price/Forward Earnings ratio of 71.62 indicates a quite expensive valuation of MYGN.
  • MYGN's Price/Forward Earnings ratio is rather cheap when compared to the industry. MYGN is cheaper than 88.97% of the companies in the same industry.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 23.54, MYGN is valued quite expensively.
Industry RankSector Rank
PE 72.5
Fwd PE 71.62
MYGN Price Earnings VS Forward Price EarningsMYGN Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
MYGN Per share dataMYGN EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 4 6 8

4.3 Compensation for Growth

  • The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates an expensive valuation of the company.
  • MYGN's earnings are expected to grow with 71.77% in the coming years. This may justify a more expensive valuation.
PEG (NY)58.7
PEG (5Y)N/A
EPS Next 2Y77.53%
EPS Next 3Y71.77%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. MYGN Dividend Analysis

5.1 Amount

  • MYGN does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

MYGN Fundamentals: All Metrics, Ratios and Statistics

MYRIAD GENETICS INC

NASDAQ:MYGN (4/10/2026, 8:00:01 PM)

After market: 4.35 0 (0%)

4.35

-0.09 (-2.03%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-23
Earnings (Next)04-30
Inst Owners103.98%
Inst Owner Change0%
Ins Owners4.54%
Ins Owner Change20.2%
Market Cap406.77M
Revenue(TTM)824.50M
Net Income(TTM)-365.90M
Analysts53.33
Price Target7.54 (73.33%)
Short Float %12.96%
Short Ratio6.31
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)234.12%
Min EPS beat(2)100%
Max EPS beat(2)368.23%
EPS beat(4)4
Avg EPS beat(4)286.44%
Min EPS beat(4)49.87%
Max EPS beat(4)627.66%
EPS beat(8)7
Avg EPS beat(8)242.45%
EPS beat(12)10
Avg EPS beat(12)184.39%
EPS beat(16)13
Avg EPS beat(16)148.66%
Revenue beat(2)0
Avg Revenue beat(2)-1.19%
Min Revenue beat(2)-1.57%
Max Revenue beat(2)-0.81%
Revenue beat(4)1
Avg Revenue beat(4)-0.78%
Min Revenue beat(4)-4.24%
Max Revenue beat(4)3.49%
Revenue beat(8)3
Avg Revenue beat(8)-0.34%
Revenue beat(12)5
Avg Revenue beat(12)0.07%
Revenue beat(16)8
Avg Revenue beat(16)0%
PT rev (1m)-4.01%
PT rev (3m)-8.34%
EPS NQ rev (1m)7.04%
EPS NQ rev (3m)-977.67%
EPS NY rev (1m)0%
EPS NY rev (3m)-15.33%
Revenue NQ rev (1m)0.04%
Revenue NQ rev (3m)-3.56%
Revenue NY rev (1m)-0.28%
Revenue NY rev (3m)-0.15%
Valuation
Industry RankSector Rank
PE 72.5
Fwd PE 71.62
P/S 0.49
P/FCF N/A
P/OCF 225.98
P/B 1.11
P/tB 2.5
EV/EBITDA N/A
EPS(TTM)0.06
EY1.38%
EPS(NY)0.06
Fwd EY1.4%
FCF(TTM)-0.27
FCFYN/A
OCF(TTM)0.02
OCFY0.44%
SpS8.82
BVpS3.94
TBVpS1.74
PEG (NY)58.7
PEG (5Y)N/A
Graham Number2.3
Profitability
Industry RankSector Rank
ROA -51.78%
ROE -99.43%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 69.93%
FCFM N/A
ROA(3y)-29.05%
ROA(5y)-19.71%
ROE(3y)-50.4%
ROE(5y)-33.33%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-0.14%
GM growth 5Y-0.26%
F-Score6
Asset Turnover1.17
Health
Industry RankSector Rank
Debt/Equity 0.33
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 51.02%
Cap/Sales 3.32%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.49
Quick Ratio 2.26
Altman-Z -0.3
F-Score6
WACC9.68%
ROIC/WACCN/A
Cap/Depr(3y)72.66%
Cap/Depr(5y)66.52%
Cap/Sales(3y)5.53%
Cap/Sales(5y)5.18%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-53.85%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%33.33%
EPS Next Y1.24%
EPS Next 2Y77.53%
EPS Next 3Y71.77%
EPS Next 5Y62.18%
Revenue 1Y (TTM)-1.56%
Revenue growth 3Y6.72%
Revenue growth 5Y5.24%
Sales Q2Q%-0.38%
Revenue Next Year5.08%
Revenue Next 2Y5.22%
Revenue Next 3Y5.18%
Revenue Next 5Y4.76%
EBIT growth 1Y23.99%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year463.6%
EBIT Next 3Y103.71%
EBIT Next 5Y71.86%
FCF growth 1Y33.33%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y120.69%
OCF growth 3YN/A
OCF growth 5Y-50.52%

MYRIAD GENETICS INC / MYGN Fundamental Analysis FAQ

What is the ChartMill fundamental rating of MYRIAD GENETICS INC (MYGN) stock?

ChartMill assigns a fundamental rating of 2 / 10 to MYGN.


What is the valuation status for MYGN stock?

ChartMill assigns a valuation rating of 2 / 10 to MYRIAD GENETICS INC (MYGN). This can be considered as Overvalued.


What is the profitability of MYGN stock?

MYRIAD GENETICS INC (MYGN) has a profitability rating of 2 / 10.


How financially healthy is MYRIAD GENETICS INC?

The financial health rating of MYRIAD GENETICS INC (MYGN) is 3 / 10.


Can you provide the expected EPS growth for MYGN stock?

The Earnings per Share (EPS) of MYRIAD GENETICS INC (MYGN) is expected to grow by 1.24% in the next year.